©TheCanadian Journal ofUrology™: International Supplement, April 2014
56.Miller K, CrawfordED, ShoreN et al. Disease control-related
outcomes from an analysis of six comparative randomised
clinical trialsofdegarelixversus luteinisinghormone-releasing
hormone (LHRH) agonists.
EurUrol Suppl
2013;12:e678-e679.
57.Smith MR, Klotz L, van der Meulen E et al. Gonadotropin-
releasing hormone blockers and cardiovascular disease risk:
analysis of prospective clinical trials of degarelix.
J Urol
2011;
186(5):1835-1842.
58.KluthLA,ShariatSF,KratzikCetal.Thehypothalamic-pituitary-
gonadal axis and prostate cancer: implications for androgen
deprivation therapy.
World JUrol
2013:1-8. Epubaheadofprint.
59.RickFG,BlockNL,SchallyAV.Agonistsof luteinizinghormone-
releasinghormone inprostatecancer.
ExpertOpinPharmacother
2013;14(16):2237-2247.
60.CrawfordED,TombalB,MillerKetal.AphaseIIIextension trial
witha1-armcrossoverfrom leuprolide todegarelix:comparison
of gonadotropin-releasing hormone agonist and antagonist
effect onprostate cancer.
JUrol
2011;186(3):889-897.
61.Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an
updatereviewof theantagonistsversusagonists.
Int JUrol
2012;
19(7):594-601.
62.Ben-JosefE,YangS-Y, JITHet al.Hormone-refractoryprostate
cancer cells express functional follicle-stimulating hormone
receptor (FSHR).
JUrol
1999;161(3):970-976.
63.Heracek J, UrbanM, Sachova J et al. The endocrine profiles in
menwith localizedand locallyadvancedprostatecancer treated
withradicalprostatectomy.
NeuroEndocrinolLett
2007;28(1):45-51.
64.Gartrell BA, Tsao C-K, Galsky MD. The follicle-stimulating
hormonereceptor:anovel target ingenitourinarymalignancies.
UrolOncol
2013;31(8):1403-1407.
65.Mariani S, Salvatori L, Basciani Set al. Expressionand cellular
localizationof follicle-stimulatinghormone receptor innormal
human prostate, benign prostatic hyperplasia and prostate
cancer.
JUrol
2006;175(6):2072-2077.
66.Radu A, Pichon C, Camparo P et al. Expression of follicle-
stimulatinghormone receptor in tumorbloodvessels.
NEngl J
Med
2010;363(17):1621-1630.
67.CrawfordED, EisenbergerMA,McLeodDGet al.Acontrolled
trial of leuprolide with and without flutamide in prostatic
carcinoma.
NEngl JMed
1989;321(7):419-424.
68.Crawford ED, Thompson IM Jr, Wilding GE et al. Bilateral
orchiectomywithorwithout flutamide formetastaticprostate
cancer.
NEngl JMed
1998;339:1036-1042.
69.Virgo KS, Taplin M-E, Loblaw DA et al. Initial hormonal
management of androgen-sensitive metastatic, recurrent, or
progressiveprostatecancer:2007updateofanAmericanSociety
ofClinicalOncologypracticeguideline.
JClinOncol2007
;25(12):
1596-1605.
70.VesperHW,BhasinS,WangCetal. Interlaboratorycomparison
studyof serum total testoseronemeasurements performedby
mass spectrometrymethods.
Steroids
2009;74(6):498-503.
71.VesperHW, RosnerW and onbehalf of The Endocrine Society
the endorsingorganizations. Toward excellence in testosterone
testing:aconsensusstatement.
JClinEndocrinolMetab
2010;95(10):
4542-4548.
72.CooksonMS,RothBJ,DahmPetal.Castration-resistantprostate
cancer:AUAGuideline.
JUrol
2013;190(2):429-438.
21
RoveandCrawford
